0000000001100322

AUTHOR

Maurizio Margaglione

showing 22 related works from this author

HCV genotype 1a and 1b: Similarities and differences in clinical features, therapeutic outcome and predictors of response

2014

medicine.medical_specialtyHepatologyGenotype 1bbusiness.industryInternal medicineGastroenterologymedicinebusinessOutcome (game theory)Digestive and Liver Disease
researchProduct

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) i…

2022

Introduction: Factor IX replacement therapy is used for treatment and prophylaxis of bleeding in haemophilia B. rIX-FP is an extended half-life albumin-fusion protein, which, in clinical studies, has demonstrated prolonged dosing intervals up to 21 days for routine prophylaxis, providing therapeutic benefit.Aims: To describe dosing frequency and consumption (primary endpoint), efficacy and safety of rIX-FP treatment during routine clinical practice in Italy.Methods: Patients with moderate/severe haemophilia B on prophylaxis with rIX-FP for >= 6 months, were enrolled in this observational study from October 2017 to February 2019 and followed-up for 2 years. Descriptive analysis included p…

ABR Trough levels annual consumption extended half-life FIX infusion frequency real lifeHematologyGeneral MedicineGenetics (clinical)Haemophilia
researchProduct

Factor V Leiden Is Associated with Repeated and Recurrent Unexplained Fetal Losses

1997

SummaryActivated protein C resistance (APCR) is responsible for most cases of familial thrombosis. The factor V missense mutation Arg506>Gln (FV Leiden) has been recognized as the commonest cause of this condition. Recently, it has been suggested that APCR is associated with second trimester fetal loss. We investigated the distribution of FV Leiden in a sample (n = 43) of Caucasian women with a history of two or more unexplained fetal losses. A group (n = 118) of parous women with uneventful pregnancies from the same ethnical background served as control. We found the mutation in 7 cases (16.28%) and 5 controls (4.24%; p = 0.011). A statistically significant difference between women with…

medicine.medical_specialtyFetusPregnancybiologybusiness.industryFactor VCase-control studyHematologymedicine.diseaseGastroenterologyEndocrinologyInternal medicineFactor V LeidenmedicineCoagulopathybiology.proteinMissense mutationActivated protein C resistancebusinessThrombosis and Haemostasis
researchProduct

ABNORMALLY HIGH THROMBOXANE BIOSYNTHESIS IN HOMOZYGOUS HOMOCYSTINURIA. EVIDENCE FOR PLATELET INVOLVEMENT AND PROBUCOL-SENSITIVE MECHANISM.

1993

Homocystinuria due to homozygous cystathionine beta-synthase deficiency is an inborn error of metabolism characterized by a high incidence of thrombosis and premature atherosclerosis. We evaluated TXA2 biosynthesis in vivo and several in vitro tests of platelet function in 11 homocystinuric patients and 12 healthy controls. In vitro, patients' platelet aggregation was within control values as were TXB2 formation, fibrinogen binding, and ATP secretion in response to thrombin. In contrast, the urinary excretion of 11-dehydro-TXB2, a major enzymatic derivative of TXA2, was > 2 SD of controls in all patients (1,724 +/- 828 pg/mg creatinine, mean +/- SD, in patients vs. 345 +/- 136 in controls, …

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentPlatelet AggregationThromboxaneProbucolHomocystinuriaInternal medicinemedicineHumansPlateletPlatelet activationChildBlood CoagulationbiologyAspirinChemistryFibrinolysisHomozygoteFibrinogen bindingThromboxanesGeneral Medicinemedicine.diseaseCystathionine beta synthaseEndocrinologyProbucolbiology.proteinlipids (amino acids peptides and proteins)FemaleHomocystinuriaCyclooxygenasemedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct

Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant

1998

A mutation in the prothrombin gene (G--A20210) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis.To determine whether the prothrombin A20210 allele is independently associated with the occurrence of venous thrombosis.Case-control study.Two thrombosis centers in southern Italy.281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls.Medical history was collected on standardized questionnaires. The presence of prothrombin G--A2020 and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function…

AdultMaleHeterozygotePathologymedicine.medical_specialtyAdolescentStatistics as TopicGastroenterologyRisk FactorsSurveys and Questionnaireshemic and lymphatic diseasesInternal medicineBlood plasmaInternal MedicinemedicineFactor V LeidenHumansPoint MutationRisk factorChildVeinAllelesAgedAged 80 and overbusiness.industryVascular diseaseFactor VGeneral MedicineMiddle AgedThrombophlebitismedicine.diseaseThrombosisPulmonary embolismVenous thrombosismedicine.anatomical_structureCase-Control StudiesChild PreschoolMutationFemaleProthrombinbusinesscirculatory and respiratory physiology
researchProduct

C-reactive protein and family history of myocardial infarction

1999

medicine.medical_specialtybiologybusiness.industryInternal medicineC-reactive proteinbiology.proteinmedicineCardiologyMyocardial infarctionFamily historyCardiology and Cardiovascular Medicinebusinessmedicine.diseaseAtherosclerosis
researchProduct

Clinical relevance of polymorphic markers of arterial thrombosis.

1997

Case-control and cross-sectional studies show that some common molecular variations (polymorphisms) of genes coding for proteins involved in atherosclerosis and thrombosis are often present in subjects who have experienced cerebrovascular or cardiovascular events. The clinical impact of the majority of polymorphic markers is disputed by prospective reports. In contrast, their pathophysiological implications and their role in monitoring parameters that are difficult to be checked by alternative means, are documented by the large majority of the reports. From the evidence available, there may be suggestion for further impact of polymorphic markers in vascular medicine. To substantiate this, n…

Genetic MarkersPathologymedicine.medical_specialtyPolymorphism GeneticGenetic inheritanceArterial diseaseVascular diseasebusiness.industryChromosome MappingThrombosisHematologyPeptidyl-Dipeptidase Amedicine.diseaseBioinformaticsThrombosisIschemiaRisk FactorsGenetic markermedicineHumansClinical significanceProspective cohort studybusinessVascular Medicine
researchProduct

Factor V Leiden, C>T MTHFR Polymorphism and Genetic Susceptibility to Preeclampsia

1997

SummaryWe performed a case-controlled study to investigate whether the FV Leiden mutation and the C>T677 polymorphism of the 5,10 methylene tetrahydrofolate reductase (MTHFR) are associated with the occurrence of preeclampsia in 96 otherwise healthy preeclamptic women and 129 parous women as controls. FV Leiden carriers were 10 (10.5%) in cases and 3 (2.3%) in controls (OR: 4.9, 95% Cl: 1.3-18.3). MTHFR TT homozygotes were 28 (29.8%) in cases and 24 (18.6%) in the control group (OR: 1.8,95% Cl 1.0-3.5). No difference in any of the polymorphisms was found between proteinuric (n = 45) and non-proteinur-ic (n = 51) patients. Moreover, MTHFR polymorphism does not affect the association betwe…

medicine.medical_specialtybiologybusiness.industryFactor VCase-control studyHematologymedicine.diseasefemale genital diseases and pregnancy complicationsPreeclampsiaEndocrinologyPolymorphism (computer science)Internal medicineMethylenetetrahydrofolate reductaseGenotypeFactor V Leidenmedicinebiology.proteinGenetic predispositionbusinessThrombosis and Haemostasis
researchProduct

PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.

1998

Abstract —Plasminogen activator inhibitor-1 (PAI-1) plasma levels have been consistently related to a polymorphism (4G/5G) of the PAI-1 gene. The renin-angiotensin pathway plays a role in the regulation of PAI-1 plasma levels. An insertion ( I )/deletion ( D ) polymorphism of the angiotensin-converting enzyme (ACE) gene has been related to plasma and cellular ACE levels. In 1032 employees (446 men and 586 women; 22 to 66 years old) of a hospital in southern Italy, we investigated the association between PAI-1 4G/5G and the ACE I/D gene variants and plasma PAI-1 antigen levels. None of the individuals enrolled had clinical evidence of atherosclerosis. In univariate analysis, PAI-1 levels we…

AdultMaleAgingmedicine.medical_specialtyAlcohol DrinkingGenotypePopulationPeptidyl-Dipeptidase ABody Mass Indexchemistry.chemical_compoundInsulin resistanceGene FrequencyInternal medicinePlasminogen Activator Inhibitor 1Blood plasmaGenotypemedicineHumanseducationAllele frequencyTriglyceridesAgedSex Characteristicseducation.field_of_studyPolymorphism GeneticbiologySmokingAngiotensin-converting enzymeMiddle Agedmedicine.diseaseCholesterolEndocrinologychemistryPlasminogen activator inhibitor-1Hypertensionbiology.proteinFemaleCardiology and Cardiovascular MedicineBody mass indexGene Deletion
researchProduct

82. Determinants of plasma plasminogen activator inhibitor-1 antigen in subjects attending a metabolic ward

1996

medicine.medical_specialtychemistry.chemical_compoundEndocrinologyAntigenchemistrybusiness.industryInternal medicinePlasminogen activator inhibitor-1MedicineHematologybusinessFibrinolysis
researchProduct

Inherited Thrombophilic Risk Factors and Venous Thromboembolism

2000

Study objectives To investigate whether the FIIA20210 mutation is associated with isolated pulmonaryembolism (PE). Design Case-control study. Setting Five thrombosis centers in southern Italy. Patients Six hundred forty-seven consecutive referredpatients with objectively documented venous thrombosis and 1,329control subjects. Measurements and results Medicalhistories were collected. The G-to-A transition at nucleotide 1691within the factor V gene (FV Leiden) and the G-to-A transition atnucleotide position 20210 within the prothrombin gene locus (FIIA20210), levels of anticoagulant factors, and levelsof antiphospholipid antibodies were determined by standard techniques.Patients with deep ven…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybiologymedicine.drug_classbusiness.industryDeep veinAnticoagulantFactor VCritical Care and Intensive Care Medicinemedicine.diseaseGastroenterologyThrombosisSurgeryPulmonary embolismVenous thrombosismedicine.anatomical_structureInternal medicinemedicineFactor V Leidenbiology.proteinRisk factorCardiology and Cardiovascular MedicinebusinessChest
researchProduct

Determining sulfur-containing amino acids by capillary electrophoresis: A fast novel method for total homocyst(e)ine human plasma

1999

A high-performance capillary electrophoresis (HPCE) method based on laser-induced fluorescence detection is presented here. It enables the determination of sulfur-containing amino acids within 15 min. Fluorescence of sulfur-containing amino acids in plasma is linear over a range of 50-150 micromol/L for L-methionine, 5-100 micromol/L for L-homocysteine, and 50-200 micromol/L for L-cysteine. For homocysteine, we were able to detect 1 fmol injected, equivalent to a plasma concentration of 10 nmol/L. A similar sensitivity is present for cysteine, an even lower one being found for methionine. The intra- and interassay relative standard deviations are < 1%. High-performance liquid chromatography…

chemistry.chemical_classificationMethionineChromatographyMolecular StructureHomocysteineClinical BiochemistryElectrophoresis Capillarychemistry.chemical_elementBiochemistrySulfurFluorescenceHigh-performance liquid chromatographyAnalytical ChemistryAmino acidchemistry.chemical_compoundCapillary electrophoresischemistryHumansAmino AcidsHomocysteineChromatography High Pressure LiquidSulfurCysteineElectrophoresis
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct

Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke

1998

Background and Purpose —The ε4 allele of the apolipoprotein E (apoE) has been related to the occurrence of myocardial infarction, but its association with ischemic stroke is controversial. We have evaluated the relation between apoE alleles and the occurrence of cerebrovascular ischemia. Methods —The apoE ε genotypes of 100 patients with a documented history of ischemic stroke without clinically apparent dementia (stroke+) and 108 subjects without such history (stroke−) were determined. The relative frequency of the apoE alleles and genotypes was estimated in 398 healthy subjects aged &lt;40 years from the same ethnic background. Results —The frequency of the apoE ε4 allele in stroke+ (0.1…

AdultMaleApolipoprotein Emedicine.medical_specialtyGastroenterologyBrain IschemiaCentral nervous system diseaseApolipoproteins EReference ValuesRisk FactorsInternal medicineOdds RatiomedicineHumansSurvivorsMyocardial infarctionRisk factorAlleleStrokeAllelesAgedAged 80 and overAdvanced and Specialized Nursingbusiness.industryDementia VascularHomozygoteCase-control studyMiddle Agedmedicine.diseaseThrombosisSurgeryItalyCase-Control StudiesFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke
researchProduct

Anticardiolipin antibodies in patients with liver disease.

1999

OBJECTIVE: Our aim was to test the hypothesis that anticardiolipin antibodies (aCL) may cause an antiphospholipid syndrome and thrombotic events in patients with liver disease. METHODS: aCL were measured in 116 healthy controls and 372 patients with liver disease of different stage and etiology: 136 cases secondary to hepatitis C virus (HCV) infection, 139 due to hepatitis B virus (HBV) infection, 69 with alcoholic liver damage, and 28 cryptogenic in origin. Prior thrombotic events were recorded. The results were related to age, gender, stage, severity, and etiology of the liver disease, as well as to the occurrence of organ- and nonorgan-specific autoantibodies. RESULTS: aCL were positive …

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseasemedicine.disease_causeGastroenterologyLiver diseaseHepatitis B ChronicAntiphospholipid syndromeInternal medicinemedicineHumansAutoantibodiesHepatitis B virusHepatologybusiness.industryLiver DiseasesGastroenterologyMuscle SmoothThrombosisOdds ratioHepatitis CHepatitis C ChronicMiddle AgedHepatitis BAntiphospholipid Syndromemedicine.diseaseLogistic ModelsAntibodies AnticardiolipinHepatocellular carcinomaChronic DiseaseImmunologyFemalebusiness
researchProduct

The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease.

1998

Abstract —A family history of ischemic events is a major determinant of coronary artery disease (CAD). Plasma levels of plasminogen activator inhibitor 1 (PAI-1) modulate this risk. A deletion/insertion polymorphism within the PAI-1 locus (4G/5G) affects the expression of this gene. We investigated the relationship between the PAI-1 4G/5G polymorphism in 1179 healthy employees of our institution and the occurrence of CAD in their first-degree relatives. A family history of documented ischemic coronary disease was assessed by a modified WHO questionnaire. The PAI-1 4G/5G polymorphism was evaluated by polymerase chain reaction and endonuclease digestion. The group with a first-degree relativ…

AdultMalemedicine.medical_specialtyCoronary DiseaseLocus (genetics)BiologyGastroenterologyMedical RecordsGenetic determinismCohort StudiesCoronary artery diseasechemistry.chemical_compoundRisk FactorsInternal medicinePlasminogen Activator Inhibitor 1medicineHumansFamily historyAlleleAgedGeneticsPolymorphism GeneticChromosome MappingOdds ratioMiddle Agedmedicine.diseasechemistryPlasminogen activator inhibitor-1Regression AnalysisFemaleCardiology and Cardiovascular MedicineBody mass index
researchProduct

Identifying human platelet glycoproteins IIb and IIIa by capillary electrophoresis.

1998

Glanzmann thrombasthenia (GT) is an inherited hemorrhagic defect due to a failure of the platelet membrane glycoprotein (GP) IIb–IIIa complex. Capillary electrophoresis (CE) analysis of solubilized platelet membranes from normal individuals showed the presence of two peaks with a migration time of 27 and 29 min, respectively. An excellent run-to-run and day-to-day reproducibility of the technique (< 1% variation of the retention time) was documented. Using an automated Ferguson method, the apparent molecular masses were 100.0 kDa and 138.5 kDa, respectively. Immunoprecipitation with monoclonal antibodies anti-GP IIIa (B59.2.1) and anti-IIb (61.9.1.3) showed the two peaks as IIIa and IIb, re…

Blood PlateletsMaleClinical BiochemistryPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet membrane glycoproteinBiochemistryAnalytical ChemistryCapillary electrophoresisThrombastheniamedicineHumansPlateletChildPolyacrylamide gel electrophoresischemistry.chemical_classificationMembrane GlycoproteinsGlanzmann's thrombastheniaCell MembraneElectrophoresis Capillarymedicine.diseaseFlow CytometryMolecular biologyPrecipitin TestsPlatelet Glycoprotein GPIIb-IIIa ComplexchemistryGlycoproteinThrombastheniaElectrophoresis
researchProduct

Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin.

2014

Background & Aims The pool of HCV genotype 1 patients likely to be cured by peg-interferon and ribavirin remains to be quantified. Methods In 1045 patients treated with peg-interferon and ribavirin, two therapeutic strategies were confronted: the first one evaluated only baseline variables associated with sustained virological response (SVR), and the second one included the rapid virologic response (RVR) in addition to baseline predictors. An 80% SVR rate was the threshold to retain a strategy as clinically relevant. Results Overall, 414 patients (39.6%) attained SVR. In the first strategy, the hierarchy of features independently associated with SVR was IL28B CC genotype (OR 5.082; CI 3.637…

MaleIL28BChronic HCV liver diseaseHepacivirusGastroenterologyPolyethylene GlycolsVirological responseresponse predictorschemistry.chemical_compoundantiviral therapyGenotypeViralChronicchronic hepatitis C; antiviral therapy; response predictorsSettore MED/12 - Gastroenterologiavirus diseasesMiddle AgedHepatitis CRecombinant ProteinsCombinationHCVFemalePredictors of response; Ribavirin; Peg-interferon; HCV; Chronic HCV liver diseaseAdultmedicine.medical_specialtyGenotypeChronic HCV liver disease; HCV; Peg-interferon; Predictors of response; Ribavirin; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; RNA Viral; Recombinant Proteins; Ribavirin; HepatologyPredictors of responseViremiaAntiviral AgentsDrug TherapyChronic hepatitisInternal medicineRibavirinmedicinechronic hepatitis CHumansDual therapyRapid Virologic ResponseAgedgenotype 1Peg-interferonHepatologybusiness.industryRibavirinInterferon-alphamedicine.diseasedigestive system diseasesSurgeryPeg interferonPegIFNchemistryRNAbusiness
researchProduct

Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance

2013

Background & Aims In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, ΔG/TT) of a new gene, designated IFN λ-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. In addition, combined genotyping of different SNPs of the IL28B locus was shown to help dissect patients most prone to SVR among those with rs12979860CT. We examined whether single or combined genotyping of two IL28B SNPs, rs12979860 and rs8099917, and ss469415590 variation might improve the prediction of SVR. Results In the study cohort of 539 pa…

MaleOncologySettore MED/09 - Medicina InternaIL28Bpeg-interferonBioinformaticsPolyethylene GlycolLinkage DisequilibriumPolyethylene GlycolsCohort StudiesIL28B/interferon lambda-3 genechemistry.chemical_compoundGene Frequencypeg-interferon/ribavirinvirus diseasesRecombinant ProteinMiddle AgedViral LoadHepatitis CRecombinant ProteinsTreatment OutcomeHCVCohortFemaleHumanAdultmedicine.medical_specialtyinterferon lambda-3 geneLocus (genetics)Single-nucleotide polymorphismBiologychronic hepatitiInternal medicineRibavirinmedicineHumansSNPAlleleGenotypingGeneinterferon lambda-4 geneAgedPolymorphism GeneticHepatologyInterleukinsRibavirinInterferon-alphaInterleukindigestive system diseaseschemistryInterferonsCohort StudieLiver International
researchProduct

The Use of Frozen-Thawed Platelet-Derived Phospholipids as a Confirmatory Test for the Diagnosis of Lupus Anticoagulants. Comparison with Two Commerc…

1999

Lupus anticoagulants (LAs) belong to acquired circulating anticoagulants interfering with phospholipid-dependent coagulation tests. Owing to the remarkable variability among patients, SSC guidelines recommend more than one test to detect and confirm the presence of LAs. However, this is an expensive procedure and greatly raises the work load of the laboratory. A standardised platelet-derived phospholipid preparation was obtained and platelet neutralisation (PNP) procedures with APTT and DRVVT reagents were performed on plasmas from 16 patients with LAs and from 41 control subjects. In comparisons, STAclot-PNP and DVVconfirm clotting assays were conducted. PNP by using APTT or DRVVT reagents…

AdultBlood PlateletsMaleinorganic chemicalsAdolescentmedicine.drug_classCoefficient of variationCoagulation testingHumansMedicineheterocyclic compoundsPlateletPhospholipidsAgedBlood coagulation testCryopreservationLupus anticoagulantChromatographySystemic lupus erythematosusbusiness.industryAnticoagulantHematologyMiddle Agedmedicine.diseaseControl subjectsenzymes and coenzymes (carbohydrates)Freeze DryingLupus Coagulation InhibitorImmunologyFemaleBlood Coagulation TestsbusinessThrombosis Research
researchProduct

A novel mutation of gene CBFA1/RUNX2 in cleidocranial dysplasia.

2007

Cleidocranial dysplasia (CCD) is an autosomal dominant skeletal dysplasia characterised by abnormal clavicles, patent sutures and fontanelles, supernumerary teeth, short stature, and a variety of other skeletal changes. The disease gene is CBFA1/RUNX2, which is mapped to chromosome 6p21. Inactivation of the CBFA1/RUNX2 gene by mutations is involved in the skeletal defects that occur in patients with CCD. CBFA1/RUNX2 controls the differentiation of precursor cells into osteoblasts and is essential for membranous as well as endochondral bone formation. In this study of a 14-yr-old boy with typical CCD phenotype, the authors found a novel CBFA1/RUNX2 gene mutation. All of the amplified segment…

MaleHeterozygoteAdolescentDNA Mutational AnalysisCore Binding Factor Alpha 1 SubunitPolymerase Chain ReactionPedigreeAdolescent Chromosomes Human Pair 6 Cleidocranial Dysplasia/genetics* Cleidocranial Dysplasia/pathology Codon Nonsense/genetics* Core Binding Factor Alpha 1 Subunit/genetics* DNA Mutational Analysis DNA Primers/chemistry Female Gene Silencing Heterozygote Humans Male Pedigree Point Mutation* Polymerase Chain Reactioncleidocranial dysplasiaCodon NonsenseCBFA1/RUNX2HumansPoint MutationChromosomes Human Pair 6Femalegene mutationGene SilencingCleidocranial DysplasiaDNA Primers
researchProduct

Fibrinogen plasma levels in an apparently healthy general population: Relation to environmental and genetic determinants

1998

SummaryElevated fibrinogen levels are an independent risk factor for cardiovascular ischemic disease. We investigated the relationship between cardiovascular ischemic risk factors, the fibrinogen Bβ-chain G/A-455 polymorphism and plasma fibrinogen levels in 989 apparently healthy subjects. Fibrinogen values were higher in subjects with C reactive protein (C-RP) &gt; 0.33 mg/dl, BMI &gt; 23.9 kg/m2, total cholesterol &gt; 4.84 mmol/l, triglycerides &gt;1.02 mmol/l, PAI-1 antigen &gt;12.2 ng/ml, carriers of the A allele, first-degree relative history of coronary artery disease, or consuming &gt;10 cigarettes per day (p &lt;0.01). Men and ethanol drinkers showed lower plasma fibrinogen levels …

education.field_of_studymedicine.medical_specialtyPathologybiologybusiness.industryPopulationC-reactive proteinHematologyFibrinogenmedicine.diseaseCoronary artery diseaseEndocrinologyQuartileInternal medicinebiology.proteinMedicineAllelebusinesseducationBody mass indexmedicine.drugCohort study
researchProduct